PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 9503370

A single plan approach for differentially dosing sequential target volumes.

L H Marsh·R K Ten Haken·H M Sandler
View original source ↗Export metadata ↓

Abstract

An in-house protocol for treatment of malignant astrocytomas requires development of a single treatment plan constructed to deliver different doses to three sequential target volumes. This single plan approach fundamentally differs from a previous protocol in which these sequential volumes were approached with three consecutive treatment plans, each tailored to a separate target, with the final target receiving a cumulative dose of 80 Gy. The intent of the revised protocol is to deliver doses to the two larger targets that are biologically equivalent (using the linear quadratic model) to the cumulative doses received by these targets in the earlier protocol, while escalating the final target dose to 90 Gy. This requires the treatment planner to manipulate the conformation of three different isodose levels simultaneously to produce a treatment plan fulfilling all protocol specifications. This paper will focus on the evolution of design for the current technique used to clinically implement this protocol.

Explore related subjects

AstrocytomaBrain NeoplasmsComputer SimulationHumansImage Processing, Computer-AssistedRadiotherapy DosageRadiotherapy Planning, Computer-AssistedJournal ArticleResearch Support, U.S. Gov't, P.H.S.

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

L H Marsh, R K Ten Haken, H M Sandler. 1997. A single plan approach for differentially dosing sequential target volumes.. https://doi.org/10.1016/s0958-3947(97)00109-x

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2001

Serum deprivation and NGF induce and modulate voltage-gated Na(+) currents in human astrocytoma cell lines.

Glial tumor cells derived from primary tissue express large voltage-gated Na(+) currents, whereas glioma cell lines usually lack this feature. We studied the effect of serum deprivation on the expression of Na(+) currents in two astrocytoma cell lines (1321N1 and A172). Serum deprivation for more than 2 days sufficed to induce large Na(+) currents in both cell lines; 300 nM of the specific blocker of voltage-gated Na(+) channels, tetrodotoxin, blocked these currents by about 85%. During serum deprivation, the cells also underwent morphological changes that were characterized by cell rounding and outgrowth of processes. Treatment with 100 ng/ml nerve growth factor (NGF) promoted these morphological changes and also accelerated the development of Na(+) currents. In 1321N1 cells, NGF increased the Na(+) current density after short serum deprivation (3--6 d) and changed several gating properties after longer serum deprivation (9--13 d). In comparison with cells from the early culture stage (3--6 d), the steady-state inactivation of the Na(+) current was shifted by -24 mV in NGF-treated cells from the late (9--13 d) culture stage. In untreated cells, this shift was only -13 mV. NGF accelerated the kinetics of inactivation and shifted the current-voltage relationship in cells from the late culture stage by -14 mV. In A172 cells, most of these effects were present already after short serum deprivation either in presence or absence of NGF. It is concluded that in astrocytoma cells, Na(+) currents are induced by serum deprivation and are modulated by NGF. This result supports the idea that NFG controls Na(+) currents in these cells by autocrine stimulation.

Astrocytoma↗
PubMed2001

A germline deletion of p14(ARF) but not CDKN2A in a melanoma-neural system tumour syndrome family.

The melanoma-astrocytoma syndrome is characterized by a dual predisposition to melanoma and neural system tumours, commonly astrocytoma. Germline deletions of the region on 9p21 containing the CDKN2A and CDKN2B genes and CDKN2A exon 1beta have been reported in kindreds, implicating contiguous tumour suppressor gene deletion as a cause of this syndrome. We describe a family characterized by multiple melanoma and neural cell tumours segregating with a germline deletion of the p14(ARF)-specific exon 1beta of the CDKN2A gene. This deletion does not affect the coding or minimal promoter sequences of either the CDKN2A or CDKN2B genes. Our results are consistent with either: (i) loss of p14(ARF) function being the critical abnormality associated with this syndrome, rather than contiguous loss of both the CDKN2A and CDKN2B genes as suggested previously; or (ii) disruption of expression of p16 by mechanisms as yet unknown.

Astrocytoma↗